Indian drug maker Suven Life Sciences Ltd announced recently it received product patents in China for two of its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.

The patents, valid until 2024 and 2025 respectively, are currently in pre-clinical development, and may be out-licensed at the stage of clinical phase-I or phase-II stage.

''We are pleased by the issuance of these patents in these countries to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally,'' said Venkat Jasti, CEO of Suven.

The granted patent claims include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer`s, Parkinson, schizophrenia and Huntington's.